Publications 2021

Broch K, Anstensrud AK, Woxholt S, Andersen GO, Gullestad L (2021)
REPLY: Clarification Regarding the Lack of Heart Failure Events in the ASSAIL-MI Trial
J. Am. Coll. Cardiol., 78 (6), 637-638
DOI 10.1016/j.jacc.2021.06.005

Broch K, Anstensrud AK, Woxholt S, Sharma K, Tollefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damas JK, Berg ES, Bjorkelund E, Bendz C, Hopp E, Kleveland O, Stensaeth KH, Opdahl A, Klow NE, Seljeflot I, Andersen GO, Wiseth R, Aukrust P, Gullestad L (2021)
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
J. Am. Coll. Cardiol., 77 (15), 1845-1855
DOI 10.1016/j.jacc.2021.02.049

Publications 2020

Anstensrud AK, Molden E, Haug HJ, Qazi R, Muriq H, Fosshaug LE, Spigset O, Oie E (2020)
Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study
Eur. J. Clin. Pharmacol., 76 (5), 673-683
DOI 10.1007/s00228-020-02832-0

Publications 2019

Anstensrud AK, Woxholt S, Sharma K, Broch K, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damas JK, Hopp E, Kleveland O, Stensaeth KH, Opdahl A, Klow NE, Seljeflot I, Andersen GO, Wiseth R, Aukrust P, Gullestad L (2019)
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
Open Heart, 6 (2), UNSP e001108
DOI 10.1136/openhrt-2019-001108

Fosshaug LE, Colas RA, Anstensrud AK, Gregersen I, Nymo S, Sagen EL, Michelsen A, Vinge LE, Oie E, Gullestad L, Halvorsen B, Hansen TV, Aukrust P, Dalli J, Yndestad A (2019)
Early increase of specialized pro-resolving lipid mediators in patients with ST-elevation myocardial infarction
EBioMedicine, 46, 264-273
DOI 10.1016/j.ebiom.2019.07.024